Odyssean LLC acquired a new stake in Doximity, Inc. (NYSE:DOCS – Free Report) during the second quarter, Holdings Channel reports. The fund acquired 114,590 shares of the company’s stock, valued at approximately $2,377,000.
Several other hedge funds and other institutional investors also recently added to or reduced their stakes in the business. Northwestern Mutual Wealth Management Co. raised its holdings in Doximity by 99.5% in the 4th quarter. Northwestern Mutual Wealth Management Co. now owns 796 shares of the company’s stock valued at $35,000 after buying an additional 397 shares during the period. Parallel Advisors LLC boosted its stake in Doximity by 111.0% during the first quarter. Parallel Advisors LLC now owns 2,560 shares of the company’s stock worth $60,000 after buying an additional 1,347 shares during the period. EverSource Wealth Advisors LLC increased its position in shares of Doximity by 937.7% during the first quarter. EverSource Wealth Advisors LLC now owns 2,833 shares of the company’s stock valued at $66,000 after acquiring an additional 2,560 shares during the last quarter. Continuum Advisory LLC purchased a new stake in shares of Doximity in the 2nd quarter valued at approximately $67,000. Finally, Farther Finance Advisors LLC lifted its holdings in shares of Doximity by 35.7% in the 4th quarter. Farther Finance Advisors LLC now owns 1,539 shares of the company’s stock worth $68,000 after acquiring an additional 405 shares during the last quarter. Institutional investors and hedge funds own 87.19% of the company’s stock.
Doximity Stock Down 2.2%
DOCS opened at $24.74 on Wednesday. Doximity, Inc. has a 52 week low of $17.15 and a 52 week high of $76.51. The business’s 50 day moving average is $22.39 and its two-hundred day moving average is $23.13. The firm has a market cap of $4.41 billion, a price-to-earnings ratio of 29.11, a price-to-earnings-growth ratio of 19.79 and a beta of 1.29.
Insider Buying and Selling at Doximity
In other Doximity news, insider Siddharth Sitaram sold 2,444 shares of the company’s stock in a transaction that occurred on Monday, June 8th. The stock was sold at an average price of $20.41, for a total transaction of $49,882.04. Following the completion of the sale, the insider directly owned 90,706 shares of the company’s stock, valued at $1,851,309.46. This represents a 2.62% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, Director Timothy S. Cabral sold 7,500 shares of Doximity stock in a transaction that occurred on Friday, August 7th. The shares were sold at an average price of $39.11, for a total value of $293,325.00. Following the completion of the transaction, the director owned 3,221 shares in the company, valued at $125,973.31. This trade represents a 69.96% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 11,714 shares of company stock worth $387,351 over the last three months. 31.80% of the stock is currently owned by insiders.
Analyst Ratings Changes
A number of research analysts have commented on DOCS shares. JPMorgan Chase & Co. upped their price target on Doximity from $26.00 to $31.00 and gave the stock a “neutral” rating in a research note on Friday, August 7th. BTIG Research lowered shares of Doximity from a “buy” rating to a “neutral” rating in a research note on Thursday, May 14th. Wolfe Research raised shares of Doximity to an “outperform” rating in a research report on Thursday, August 13th. Citigroup lowered shares of Doximity to an “underperform” rating in a research note on Monday, June 29th. Finally, Mizuho cut their target price on shares of Doximity from $34.00 to $26.00 and set a “neutral” rating on the stock in a research note on Thursday, May 14th. Two equities research analysts have rated the stock with a Strong Buy rating, seven have assigned a Buy rating, twelve have issued a Hold rating and four have given a Sell rating to the company. According to MarketBeat, the company presently has an average rating of “Hold” and an average target price of $32.43.
Get Our Latest Stock Report on Doximity
Doximity Company Profile
Doximity, trading as DOCS, operates a digital professional network and communications platform designed primarily for clinicians. Headquartered in San Francisco, the company connects physicians, nurse practitioners, physician assistants and other healthcare professionals, providing tools that streamline clinical communication, telehealth delivery and access to specialty-specific medical information. Its platform is positioned as a professional hub where clinicians manage their workflows, stay current with medical news and collaborate securely with peers.
The company’s offerings include secure messaging and video telehealth capabilities that enable clinicians to consult with patients and colleagues while protecting patient information.
Read More
- Five stocks we like better than Doximity
- Pathward’s Credit Scare Tests Its Comeback Story
- Wiring the AI Boom: Rumble’s $13.7B Pivot
- StoneX: Too Far Too Fast?
- DICK’s Sporting Goods Faces Pain Now for a Bigger Prize
Want to see what other hedge funds are holding DOCS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Doximity, Inc. (NYSE:DOCS – Free Report).
Receive News & Ratings for Doximity Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Doximity and related companies with MarketBeat.com's FREE daily email newsletter.
